Abstract 1524P
Background
Phase III studies (SPOTLIGHT and GLOW) showed that combining anti-Claudin18.2 (CLDN18.2) antibody with chemotherapy significantly improved outcomes for first-line treatment for G/GEJ cancer with high CLDN18.2 expression. TST001 is a potential best-in-class antibody with improved CLDN18.2 affinity and enhanced ADCC effect, leading to anti-tumor activity in low to medium CLDN18.2 expression gastric cancer animal models.
Methods
Cohort C from Transtar102 study was designed to explore the safety and efficacy of TST001 plus CAPOX as 1st- line treatment in advanced G/GEJ cancer (NCT04495296–study Transtar102). Positive CLDN18.2 (membranous staining intensity ≥1+ in ≥10% of tumor cells) assessed centrally using the IHC 14G11 LDT assay was required in the expansion phase only.
Results
As of 21 April 2023, 64 patients have been dosed with TST001 plus CAPOX, including 15 patients who received TST001 at doses ranging from 1 to 8 mg/kg Q3W in the dose escalation phase and 49 patients at 6 mg/kg in the dose expansion phase. The median follow-up is 197.5 days. The most common treatment related adverse events are nausea (70.3%), vomiting (53.1%) and hypoalbuminemia (75%) with grade 3 being 1.6% each. 42 out of the 49 patients in the 6 mg/kg expansion cohort have measurable lesions and had at least one post-treatment tumor assessment, with 28 (66.7%) achieving partial response (confirmed and unconfirmed). Across all doses, the objective response rate (confirmed and unconfirmed) is 65.4%, the estimated median progression-free survival is 9.5 months, and the estimated median duration of response is 9.9 months. 38 of 49 patients are CLDN18.2 positive with no notable difference in efficacy per CLDN18.2 level. Overall survival is immature and will be updated at the time of the conference.
Conclusions
TST001 plus CAPOX as first-line treatment for patients with G/GEJ cancer demonstrated good safety and tolerability. Encouraging anti-tumor activities have been observed regardless of the CLDN18.2 expression levels, including expression as low as ≥10% tumor cells staining ≥1+, <40% tumor cells staining <2+ or 3+. Overall survival data will be presented.
Clinical trial identification
NCT04495296.
Editorial acknowledgement
Legal entity responsible for the study
Suzhou Transcenta Therapeutics Co, Ltd.
Funding
Suzhou Transcenta Therapeutics Co, Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1489P - To investigate the differences in efficacy between immunotherapy and combined immunotherapy in elderly patients with non-small cell lung cancer
Presenter: Ye Mao
Session: Poster session 21
1490P - Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
Presenter: Mustafa Bozkurt
Session: Poster session 21
1491P - PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients
Presenter: Jeongmin Seo
Session: Poster session 21
1493P - A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Presenter: Tomasz Jankowski
Session: Poster session 21
1495P - Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Presenter: Ana Baramidze
Session: Poster session 21
1496P - Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Paul Takam Kamga
Session: Poster session 21
1497P - Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
Presenter: Yawen Bin
Session: Poster session 21